Does Buffett still have the magic touch? It seems as if Japan does not get a lot of respect from external investors.
In the second of a series on Australian biotech success stories, here are some more representatives of the fascinating medical device cohort on the ASX. Medical Developments International (MVP, $5.97) Market capitalisation: $391 million Three-year total return: 6.3% a year Analysts’ consensus target price: $8.61 (Thomson Reuters) Medical Developments International is the company behind the…
Semiconductors would have to be one of the most pervasive and critical pieces of technology in our daily lives – but they are usually not thought about very much. They certainly don’t seem to get the investment love like they should, or get talked about as much as, say, the FAANG stocks or electric vehicle…
Troy is a Partner and Adviser at Koda Capital. Troy is a FASEA-compliant financial adviser holding a Bachelor of Commerce and SMSF Specialist Advisor designation. He became a member of the Inside Network and an inaugural member of the Advisory Committee; seeking to learn from his peers and share his own wisdom from many years in the industry.
It’s hardly a fair comparison, is it? To put REA Group alongside Domain Holdings?
One of the hottest tech stocks in the US market at present – which is really saying something – is advertising technology company The Trade Desk.
In the first of a series on Australian biotech success stories, we start with some of the outstanding medical device stocks on the ASX.
Nucleus Wealth has launched an SMA that allows investors to take a stand on diversity
With July coming to a close, it’s time for reporting season – and this year, it’s not going to be pretty.
While more and more Australian investors get comfortable with investing overseas, it’s fair to assume that Latin America is not on most people’s map of the investable universe – “there be dragons,” as the old mariners used to say.
